Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, has entered into a companion diagnostic development collaboration with BeiGene, a clinical-stage biopharmaceutical company developing molecularly-targeted and immuno-oncology drugs for the treatment of cancer, to accelerate precision medicine in oncology.
Under the agreement, BeiGene will use Myriad’s myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the clinical development of its novel PARP inhibitor, BGB-290. Specific terms of the deal were not disclosed.
“We are excited to collaborate with BeiGene to help identify patients who stand to benefit the most from treatment with BGB-290,” said Mark C. Capone, president and CEO, Myriad Genetics. “As the pioneer in companion diagnostics for PARP inhibitors, we recognize that precision medicine only can be achieved by molecularly matching patients to the right therapy. Together with BeiGene, we are in a unique position to integrate advanced genetic information into clinical practice and achieve better patient outcomes."
BRACAnalysis CDx is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens.
Myriad's myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents.
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.